Haloperidol Lactate

CHEMBL4297147 Phase 4 Disetujui Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

465.9 g/mol

LogP

—

Phase

4

A lactate salt form of haloperidol used in injectable formulations for the rapid treatment of acute psychosis, severe agitation, or delirium in hospital settings. It provides fast-acting antipsychotic and sedating effects when administered intramuscularly or intravenously. This form is preferred for acute interventions due to its rapid onset compared to oral preparations.

Berat Molekul

465,9000 g/mol

TPSA

98,10 Å²

Area Terapeutik

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Pain Management Non-Small Cell Lung Cancer Alzheimer's Disease Epilepsy Migraine Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Insomnia Chronic Kidney Disease Stroke Obesity Type 2 Diabetes Hypertension Breast Cancer Chronic Pain Heart Failure Prostate Cancer Colorectal Cancer

Mekanisme Kerja

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanisme

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

Struktur 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CC(O)C(=O)O.O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1

InChI

InChI=1S/C21H23ClFNO2.C3H6O3/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16;1-2(4)3(5)6/h3-10,26H,1-2,11-15H2;2,4H,1H3,(H,5,6)

Molecular Formula

C24H29ClFNO5

HBD / HBA

3 / 7

Ikatan yang Dapat Dirotasi

7

Atom Berat

32

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

A lactate salt form of haloperidol used in injectable formulations for the rapid treatment of acute psychosis, severe agitation, or delirium in hospital settings. It provides fast-acting antipsychotic and sedating effects when administered intramuscularly or intravenously. This form is preferred for acute interventions due to its rapid onset compared to oral preparations.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Haloperidol Lactate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4297147. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 16051968. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Mencari informasi yang ramah bagi pasien?

Haloperidol Lactate di PillFYI

Struktur

Data Cepat

Rumus: C24H29ClFNO5
Sinonim: 1

Tautan Eksternal

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.